FDA Rejects Epidermolysis Bullosa Cell Therapy and Requests Additional Manufacturing Data
source: shutterstock.com

FDA Rejects Epidermolysis Bullosa Cell Therapy and Requests Additional Manufacturing Data

Clinical-stage biotechnology company Abeona Therapeutics ("Abeona") is working to develop a novel cell therapy for people living with recessive dystrophic epidermolysis bullosa (RDEB), a rare genetic skin disorder characterized by…

Continue Reading FDA Rejects Epidermolysis Bullosa Cell Therapy and Requests Additional Manufacturing Data